Basilea Pharmaceutica (LTS:0QNA) Additional Paid-In Capital : CHF1,042.0 Mil(As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Additional Paid-In Capital?

Basilea Pharmaceutica's quarterly additional paid-in capital increased from Dec. 2022 (CHF1,037.1 Mil) to Jun. 2023 (CHF1,040.4 Mil) and increased from Jun. 2023 (CHF1,040.4 Mil) to Dec. 2023 (CHF1,042.0 Mil).

Basilea Pharmaceutica's annual additional paid-in capital increased from Dec. 2021 (CHF1,029.8 Mil) to Dec. 2022 (CHF1,037.1 Mil) and increased from Dec. 2022 (CHF1,037.1 Mil) to Dec. 2023 (CHF1,042.0 Mil).

Basilea Pharmaceutica Additional Paid-In Capital Historical Data

The historical data trend for Basilea Pharmaceutica's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Additional Paid-In Capital Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

927.34

982.44

1,029.80

1,037.12

1,042.00

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,029.80	1,031.63	1,037.12	1,040.37	1,042.00

Basilea Pharmaceutica Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Basilea Pharmaceutica Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BSLNz:UK BSLN:Switzerland

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines